Bio
Nigel is a Partner with Encore Ventures. He joined as a result of Encore's acquisition of the bulk of 3i's European venture portfolio in 2009. Prior to joining Encore Nigel had been with 3i for 12 years, becoming a Partner in 2006, and ultimately leading the venture team's healthcare activities across Europe and the US. He was responsible for leading deals such as Domantis, Apatech and Arakis, and in working closely with the management teams to create and realise signficant value. Nigel remains a Director on the Board of Apatech. Nigel studied chemistry at the University of Oxford, before completing a PhD at the University of Durham. His research activities were focused on aspects of computational chemistry and rational drug design and saw him join the Cambridge Crystallographic Data Centre (CCDC) in 1994, where he spent two years working on new product design and projects for pharmaceutical company clients. He completed an MBA at Warwick Business School, before joining 3i in 1997.
Career
|
Imperial Innovations Ltd |
||
|
DFJ Esprit LLPVenture capital firm. |